Part 1 of this phase III study was a randomized , double-blind , parallel-group , placebo-controlled , multicenter study of caregiver administered diazepam auto-injector ( AI ) in subjects with acute repetitive seizures ( ARS ) and demonstrated that diazepam AI was well-tolerated and significantly more effective than placebo AI in delaying the time to next seizure or rescue .